Introduction
============

Seipinopathy is an autosomal dominant, neurodegenerative disease caused by mutations of *Berardinelli-Seip Congenital Lipodystrophy 2* (*BSCL2*) gene ([@B1]). While loss-of-function mutations in the *BSCL2* gene causes lipodystrophy, heterozygous missense mutations, such as p.N88S, p.S90L, p.S90W and p.R96H, have been identified as the cause of seipinopathy through the gain of a toxic function ([@B2]-[@B4]). Seipinopathy has several phenotypes that are described as follows ([@B5]). The Silver syndrome phenotype is characterized by amyotrophy of the small hand muscles and spasticity of the lower limbs. The distal hereditary motor neuropathy type V (dHMN-V) phenotype is characterized by weakness or amyotrophy, primarily in the small hand muscles and late-onset gait disturbance. The hereditary spastic paraparesis phenotype is characterized by spastic paraparesis in the lower limbs. The Charcot-Marie-Tooth disease (CMT) phenotype is characterized by distal muscle weakness and amyotrophy of the lower limbs (rather than the upper limbs). Pyramidal signs are occasionally seen, and depending on the presence or absence of sensory disturbance, the CMT phenotype is further divided into spinal CMT and hereditary motor and sensory neuropathy type Ⅱ (HMSN-Ⅱ). Thus, seipinopathy can lead to symptoms that mimic amyotrophic lateral sclerosis. In fact, mutations of the *BSCL2* gene have been known to cause motor neuron degeneration through endoplasmic reticulum stress ([@B1]). Seipinopathy should be considered in patients with both upper and lower motor neuron involvement.

Case Report
===========

We herein report the case of a 63-year-old Japanese woman who was not good at physical activities like running when she was an elementary school student. After 30 years of age, she gradually developed walking difficulty. She noticed weakness and atrophy in both hands at 60 years of age and both legs at 63 years of age, without body weight loss. Her paternal grandfather and father also had walking difficulty, but they lived until 88 and 91 years of age, respectively. Her elder son had pes cavus. A physical examination revealed bilateral hyperreflexia of the biceps, triceps, brachioradialis, and knee, as well as pes cavus and distal dominant weakness and atrophy of both hands and legs ([Fig. 1](#g001){ref-type="fig"}, [2](#g002){ref-type="fig"}). However, a careful examination revealed no fasciculation. The patient was negative for Babinski and Chaddock signs, and showed an indifferent planter response; however, a left Trömner sign was noted. A cranial nerve and sensory examination (both superficial and deep sensation), blood and cerebrospinal fluid tests, magnetic resonance imaging of the head and cervical vertebrae, and sensory nerve conduction studies all revealed normal findings. Motor nerve conduction studies showed normal conduction velocities with decreased compound muscle action potentials (CMAPs) bilaterally in the tibial nerves and the right median nerve ([Table](#t001){ref-type="table"}). Needle electromyography revealed chronic neurogenic changes in the bilateral first dorsal interossei and the tibialis anterior. The central conduction time was not evaluated. A genetic analysis revealed a heterozygous mutation of the p.N88S in *BSCL2* gene ([Fig. 3](#g003){ref-type="fig"}).

![The patient showed characteristic atrophy of both hands, which was more severe in thenar eminence than in hypothenar eminence.](1349-7235-57-0613-g001){#g001}

![a-c: The patient showed distal dominant atrophy of both legs, including pes cavus. These features are often seen in Charcot-Marie-Tooth disease.](1349-7235-57-0613-g002){#g002}

###### 

Nerve Conduction Studies.

  Motor nerve study     Lat (ms)   CMAP (mV)   CV (m/s)
  --------------------- ---------- ----------- ----------
  Right median nerve                           
  Wrist                 2.76       4.73        59.7
  Elbow                 5.94       3.46        
  Right ulnar nerve                            
  Wrist                 2.9        12.02       68.5
  Elbow                 6.98       12.26       61.3
  Right tibial nerve                           
  Ankle                 2.85       0.33        39.3
  Knee                  12         0.25        
  Left tibial nerve                            
  Ankle                 3.65       0.22        40.9
  Knee                  12.2       0.24        
                                               
  Sensory nerve study              SNAP (μV)   CV (m/s)
  Right median nerve               16.2        61.9
  Right ulnar nerve                11.3        57.3
  Left sural nerve                 5.2         54.7

Lat: latency, ms: milliseconds, CMAP: compound muscle action potential, mV: millivolt, CV: conduction velocity, m/s: meter/second, SNAP: sensory nerve action potential

![The chromatogram indicated that the patient was heterozygous for a p.N88S mutation in the *BSCL2* gene (arrow).](1349-7235-57-0613-g003){#g003}

Discussion
==========

Numerous cases of seipinopathy have been reported in Europe; thus, it was considered to only occur in Europe. However, four cases of seipinopathy have been reported (two cases each) in China and Korea ([@B3],[@B6]-[@B8]). Taiwanese cases of seipinopathy with a heterozygous mutation of p.S90L and p.R96H in the *BSCL2* gene were also reported in 2016 ([@B4]). To the best of our knowledge, this is the first report of seipinopathy in a Japanese patient (with the exception of meeting abstracts) with both upper and lower motor symptoms. As seipinopathy is a broad-spectrum disease, it may often be misdiagnosed; thus, the incidence around the world may be higher than reported. In our case, the presence of pes cavus, distal dominant weakness, and atrophy of both arms and legs suggested peripheral neuropathy, and at first we assumed that these features were suitable for typical CMT. However, sensory disturbance was not seen and the co-existing pyramidal signs \[i.e., Trömner sign (only left-side) and bilateral hyperreflexia\] suggested the involvement of upper motor neurons, irrespective of the absence of Babinski and Chaddock signs. Thus, the clinical diagnosis was dHMN with spasticity ([@B9]) or HMSN-V (CMT with spasticity). A genetic analysis confirmed seipinopathy mimicking spinal CMT with a heterozygous mutation of p.N88S in the *BSCL2* gene. No specific signs or symptoms suggestive of endoplasmic reticulum stress, which plays a causative role in neurodegeneration, were noted. Thus, there may not be an effective treatment at present.

In conclusion, seipinopathy should be considered in patients with both upper and lower motor neuron impairment. Several cases of seipinopathy were recently reported in Asia, and there may be more patients in Japan. Since seipinopathy sometimes progresses slowly, a family history of seipinopathy may not be present. However, a genetic analysis is essential for making the correct diagnosis.
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